The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: Analysis of data from clinical trial and post-marketing surveillance settings

Multiple Sclerosis Journal

Volumn 17, Issue 4, 2011, Pages 431-440

  Sandberg Wollheim, Magnhild ^a   Kornmann, Gabrielle ^b,c   Bischof, Dorina ^b,c   Moraga, Margaretha Stam ^b,c   Hennessy, Brian ^b,c   Alteri, Enrica ^b,c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b MERCK SERONO S A   (Switzerland)

^c MERCK KGAA   (Germany)

Author keywords

database; long term; malignancy; multiple sclerosis; safety; subcutaneous interferon beta 1a

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; PLACEBO;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG SAFETY; HODGKIN DISEASE; HUMAN; LUNG CANCER; MELANOMA; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NERVOUS SYSTEM TUMOR; NONHODGKIN LYMPHOMA; OPEN STUDY; OVARY CANCER; PARALLEL DESIGN; POSTMARKETING SURVEILLANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THYROID CANCER; TREATMENT DURATION; UTERINE CERVIX CANCER; UTERUS CANCER;

EID: 79954622175     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458511403642     Document Type: Article

References (27)

1. Kingwell E. and Tremlett H. Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients? Expert Rev Neurother 2009 ; 9: 1263 1265.
2. European Medicines Agency. Tysabri summary of product characteristics. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000603/human-med-001119.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d125. Accessed 14 Oct 2010.
3. Food and Drug Administration. Novantrone prescribing information. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.Overview&DrugName=NOVANTRONE. Accessed 14 Oct 2010.
4. PRISMS (Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998 ; 352: 1498 1504.
5. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996 ; 39: 285 294. (Pubitemid 26100751)
6. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 ; 43: 655 661.
7. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J., Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995 ; 45: 1268 1276.
8. Moller H., Kneller RW, Boice Jr JD and Olsen JH Cancer incidence following hospitalization for multiple sclerosis in Denmark. Acta Neurol Scand 1991 ; 84: 214 220.
9. Midgard R., Glattre E., Gronning M., Riise T., Edland A. and Nyland H. Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand 1996 ; 93: 411 415. (Pubitemid 26232751)
10. Wynn DR, Kurland LT, O'Fallon WM and Rodriguez M. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 1990 ; 40: 780 786. (Pubitemid 20159613)
11. Sumelahti ML, Pukkala E. and Hakama M. Cancer incidence in multiple sclerosis: a 35-year follow-up. Neuroepidemiology 2004 ; 23: 224 227. (Pubitemid 39179151)
12. Bahmanyar S., Montgomery SM, Hillert J., Ekbom A. and Olsson T. Cancer risk among patients with multiple sclerosis and their parents. Neurology 2009 ; 72: 1170 1177.
13. Nielsen NM, Rostgaard K., Rasmussen S., Koch-Henriksen N., Storm HH, Melbye M., et al. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 2006 ; 118: 979 984. (Pubitemid 43157674)
14. Hjalgrim H., Rasmussen S., Rostgaard K., Nielsen NM, Koch-Henriksen N., Munksgaard L., et al. Familial clustering of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst 2004 ; 96: 780 784. (Pubitemid 38771823)
15. Goldacre MJ, Seagroatt V., Yeates D. and Acheson ED Skin cancer in people with multiple sclerosis: a record linkage study. J Epidemiol Community Health 2004 ; 58: 142 144. (Pubitemid 38130483)
16. Fois AF, Wotton CJ, Yeates D., Turner MR and Goldacre MJ Cancer in patients with motor neuron disease, multiple sclerosis, and Parkinson's disease: record-linkage studies. J Neurol Neurosurg Psychiatry 2010 ; 81: 215 221.
17. Achiron A., Barak Y., Gail M., Mandel M., Pee D., Ayyagari R., et al. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat 2005 ; 89: 265 270. (Pubitemid 43293074)
18. Lebrun C., Debouverie M., Vermersch P., Clavelou P., Rumbach L., de Seze J., et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler 2008 ; 14: 399 405. (Pubitemid 351676435)
19. Ferlay J., Bray F., Pisani P. and Parkin D. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide, IACR CancerBase, No 5, version 20. IARC Press, 2004.
20. Surveillance, Epidemiology, and End Results (SEER). Cancer statistics review, National Cancer Institute 2002-2006. http://www.seer.cancer.gov. Accessed 28 Aug 2007.
21. Breslow NE and Day NE Statistical methods in cancer research. Volume I -The analysis of case-control studies. IARC Sci Publ 1980 ; 32: 5 338.
22. Ellis R. and Boggild M. Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it? Mult Scler 2009 ; 15: 505 508.
23. Lentsch EJ, Gillespie M., Goddard JC, Wilhoit C., Rumboldt Z., Hoda RS, et al. Thyroid, papillary carcinoma, early. http://emedicine.medscape.com/ article/849000-overview. Accessed 22 Jan 2010.
24. National Cancer Institute. http://seer.cancer.gov/csr/1975-2006/browse- csrphp?section=26&page=sect-26-table04html. Accessed 17 Nov 2009.
25. Penn I. Malignancies associated with immunosuppressive or cytotoxic therapy. Surgery 1978 ; 83: 492 502. (Pubitemid 8339549)
26. Pedersen-Bjergaard J. and Rowley JD The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994 ; 83: 2780 2786. (Pubitemid 24142706)
27. Hazell L. and Shakir SA Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006 ; 29: 385 396.